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Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelABSTRACT Even though the Toll-like receptor (TLR) pathway is integral to inflammatory defense mechanisms, its excessive
signaling may be devastating. Cells have acquired a cascade of strategies to regulate TLR signaling by targeting protein-protein
interactions, or ubiquitin chains, but the details of the inhibition mechanisms are still unclear. Here, we provide the structural
basis for the regulation of TLR signaling by constructing architectures of protein-protein interactions. Structural data suggest
that 1) Toll/IL-1R (TIR) domain-containing regulators (BCAP, SIGIRR, and ST2) interfere with TIR domain signalosome forma-
tion; 2) major deubiquitinases such as A20, CYLD, and DUBA prevent association of TRAF6 and TRAF3 with their partners,
in addition to removing K63-linked ubiquitin chains that serve as a docking platform for downstream effectors; 3) alternative
downstream pathways of TLRs also restrict signaling by competing to bind common partners through shared binding sites.
We also performed in silico mutagenesis analysis to characterize the effects of oncogenic mutations on the negative regulators
and to observe the cellular outcome (whether there is/is not inflammation). Missense mutations that fall on interfaces and
nonsense/frameshift mutations that result in truncated negative regulators disrupt the interactions with the targets, thereby
enabling constitutive activation of the nuclear factor-kappa B, and contributing to chronic inflammation, autoimmune diseases,
and oncogenesis.INTRODUCTIONToll-like receptors (TLRs) play pivotal roles in immune
responses against invading pathogens. They signal through
major pathways and give rise to inflammation (1,2). Defects
in TLR signaling predispose individuals to infections (3).
Over-activation can result in chronic inflammatory and
autoimmune diseases and contribute to oncogenesis (3–6).
To retain a delicate balance between activation and inhibi-
tion, and avoid detrimental effects of excessive inflam-
mation, TLR signaling is strictly regulated (7,8). Here, we
aim to better understand the mechanisms of negative regu-
lation of the TLR pathway to obtain insights into how the
balance is established and the immunological homeostasis
is achieved.
TLRs get activated when pathogenic particles, pathogen-
associated molecular patterns, as well as endogenous ligands
of damaged tissues, damage-associated molecular patterns,
bind to their extracellular leucine-rich repeats, resulting in
dimerization of their leucine-rich repeats and cytoplasmic
Toll/IL-1R (TIR) domains (9). Through their TIR domains,
they recruit other TIR domain-containing adaptors, such
as Mal, myeloid differentiation primary response protein
(MyD88), TRIF-related adaptor molecule (TRAM), and
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0006-3495/15/09/1214/13(TRIF) and form TIR domain signalosomes, multimeric
protein assemblies. The TIR domain signalosome either
comprises TLR/Mal/MyD88 or TLR/TRAM/TRIF (10).
Subsequently, MyD88-dependent TIR domain signalosome
recruits IRAK4, IRAK2/IRAK1, and TRAF6, which lead
to activation of the nuclear factor-kappa B (NF-kB) and
mitogen-activated protein kinases (MAPKs), and transcrip-
tion of proinflammatory cytokines, like interleukin (IL)-1b
and tumor necrosis factor (TNF)-a (1). The TRIF-dependent
TIR domain signalosome employs TRAF3 to activate inter-
feron-regulatory factors (IRFs) to induce transcription of
antiviral interferons (IFNs) and antiinflammatory IL-10
(11,12).
Negative regulation of TLR signaling takes place at
multiple steps, ranging from extracellular soluble decoy
TLRs, to transmembrane and intracellular inhibitors such
as those that contain TIR domain (6,7). At almost each
step in the TLR signaling cascade, protein interactions or
ubiquitin (Ub) chains are targeted by one or more inhibi-
tors (Fig. 1). The presence of several checkpoints and the
redundancy of negative regulators suggest that regulation
can be achieved by a cascade of regulators, indicating
that a particular inhibitor may be essential but not
enough to fine-tune signaling (7), or that different regula-
tors may take action in different tissue types or at different
times. Although some inhibitors are constitutively ex-
pressed, others are upregulated upon TLR stimulation.http://dx.doi.org/10.1016/j.bpj.2015.06.048
FIGURE 1 Negative regulators take action at
almost all steps of TLR signaling. Red-labeled
edges show the negative regulators that turn off
the TLR signaling. The bolded red edges are the
interactions that are modeled here. Blue-labeled
edges are negative regulations from the parallel
downstream paths to the conventional proinflam-
matory path. They switch the signaling path, not
terminate the signal. To see this figure in color,
go online.
Regulation of TLR-Meditated Inflammation 1215TLR-induced apoptosis comes into play when negative reg-
ulators fail and the cell becomes overactive (7). Alternative
downstream paths of TLR signaling are competitive (10),
limiting signaling through the temporally outcompeted
pathways. Here, we focus on cytoplasmic and transmem-
brane regulators to elucidate the mechanisms through
which they attenuate TLR signaling and the resulting
inflammation.MATERIALS AND METHODS
Building structures of protein-protein interaction
complexes
We modeled the architectures of interaction complexes of the negative
regulators with the proteins in TLR pathway by exploiting PRISM (protein
interactions by structural matching) (13–15). PRISM is a knowledge-based
algorithm. It employs prior interface (template) data of known crystal/
NMR structures of protein complexes and predicts structures of novel
complexes that the target proteins can potentially form. It searches for
template interface motifs on the surface of the target proteins, taking
into account geometrical complementarities and hotspot conservation.
The inputs of PRISM are unbound protein structures and the template
interface data set. The outputs are structures of bound protein-protein
interaction (PPI) complexes. PRISM structurally aligns the interfaces
to query proteins first. Next, there comes a filtering step, where a combi-
nation of structural and evolutionary thresholds, i.e., root mean-square
deviation and number of matching hotspots, are applied. At the last
step, output models are scored and the flexibly refined to relieve possible
steric clashes by FiberDock (16). FiberDock assigns a binding energy
score by taking van der Waals interactions, partial electrostatics, and
hydrogen and disulfide bonds into account (16). An energy score
below 10 indicates a favorable interaction (14,17,18). PRISM is much
faster than classical docking tools and it achieved almost 100% success
in predicting the correct conformation of the complex structure (87 out
of 88 cases) (19).Modeling of proteins with unknown structures
PRISM requires 3D structures of target proteins to model the complex
structures of the targets. If the structure of a given target protein is missing
from the Protein Data Bank (PDB), we model it by the I-TASSER server
(20). TIR domain structures of B-cell adaptor for PI3K (BCAP), single
immunoglobulin IL-1R-related molecule (SIGIRR), and ST2 have not
been resolved yet. We built a model of BCAP TIR domain (10–144 resi-
dues). The template structures used to build the BCAP TIR domain struc-
ture are 3h16A (crystal structure of a bacteria TIR domain, PdTIR from
Paracoccus denitrificans), 3ub2A (TIR domain of Mal/TIRAP), 4lqcA
(the crystal structures of the Brucella protein TcpB and the TLR adaptor
protein TIRAP show structural differences in microbial TIR mimicry),
and 4c6sA (crystal structure of the TIR domain from the Arabidopsis thali-
ana disease resistance protein RRS1). Sequence identities, coverage, and
normalized Z-scores between the query proteins and the templates are given
in Table S1 in the Supporting Material.
The SIGIRRTIR domain structure was also missing in the PDB. We built
its model (163–310 residues) and the template used is 1t3gA (TIR domain
of human IL-1RAPL).
We also modeled the ST2 TIR domain (375–558 residues) and the
templates are 1t3gA, 3j0aA (homology model of human TLR5 fitted into
an electron microscopy single-particle reconstruction), and 1fyvA (TIR
domain of human TLR1).
Finally, we built a model of the TLR4 TIR domain. The templates are
1fyvA, 3j0aA, and 1fyxA (TLR2 TIR domain).Mapping clinically observed mutations onto the
interfaces of negative regulators and in silico
mutagenesis
We obtained clinically observed mutation data from the cBioPortal for
Cancer Genomics (The Cancer Genome Atlas, TCGA) (21). The residue
numbers in the pdb files are corrected according to the FASTA sequences.
We mapped the mutations onto the structures of negative regulators and
performed in silico mutagenesis by the MutateAminoAcid function of
the Discovery Studio molecular visualizer (Discovery Studio 3.5, Accelrys,
San Diego, CA), for the ones that fall onto the interface residues or the firstBiophysical Journal 109(6) 1214–1226
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by theHotRegion database, which uses conservation, accessible surface area
and pair potentials (22). We reran PRISMwith the mutant protein structures
to checkwhether themutation abolishes the interaction. If interactions of the
mutant structures have a binding energy score higher than that of the wild-
type, we then conclude that this mutation is destabilizing. We calculated
the number of hydrogen bonds and salt bridges in complexes with both
wild-type and mutant structures by using the PDBePISAweb server (23).RESULTS AND DISCUSSION
Through cooperative cellular network linkages, multivalent
oligomeric proteins display efficient enzymatic reactions
and amplify signal (24,25). These large protein assemblies
are formed either by direct PPIs or by Ub chains attached
to proteins that serve as a dynamic, allosteric scaffold.
These scaffolds not only bring proteins together; the shifting
landscape that they orchestrate preorganizes the ensembles
for subsequent binding and catalytic events (26). The signal
that these elicit propagates across the network (27). Cells
acquired strategies to block cellular functions such as
inflammation by targeting proteins, PPIs, and Ub chains.
At almost each step of the TLR signaling cascade, one
or more regulators take action to constrain NF-kB activa-
tion. In addition, parallel downstream paths also restrict
inflammation because they compete with the conventional
MyD88-dependent proinflammatory pathway (10) (Fig. 2).
Below, we describe the negative regulators focusing on
the structural basis of how they forestall signaling.TIR domain-containing negative regulators
Upon stimulation, TLRs dimerize and recruit TIR domain-
containing adaptors to form either MyD88- or TRIF-depen-Biophysical Journal 109(6) 1214–1226dent TIR domain signalosomes. In our recent study (10), we
have provided structural models for these two signalosomes.
We showed that they are competitive and cannot form
simultaneously on the same receptor dimer. Apart from
Mal, MyD88, TRAM, and TRIF, there are also other TIR
domain-containing proteins, which act as negative regu-
lators of TLR signaling. These include BCAP (5), SIGIRR
(28), and ST2 (29), which are suggested to interfere with
the assembly of TIR domain signalosome. Below, we
explain the regulation mechanism of these three TIR domain
containing negative regulators structurally and provide
models for how they impede TLR signaling.BCAP
Besides MyD88- and TRIF-dependent downstream paths,
the PI3K pathway can also be activated upon TLR stimula-
tion and serve as another parallel pathway of TLRs (5,30).
Although the mechanism of TLR-mediated proinflamma-
tory NF-kB and MAPK activation has been investigated
extensively, the stimulation mechanism of PI3Ka, a lipid
kinase, is still unknown (6). BCAP is a TIR domain-contain-
ing adaptor protein that links TLRs to PI3K/Akt pathway
(6). BCAP needs to be tyrosine-phosphorylated at its
YXXM motif to interact with the SH2 domain of the regu-
latory subunit (p85) of PI3Ka (3,5). TLR activation in-
creases the phosphorylated BCAP in the membrane, which
helps recruit activated PI3K to the membrane where its
lipid substrate, phosphoinositide-4,5-bisphosphate, is found
(5). If TLR is stimulated and the BCAP level is low, elevated
expression of proinflammatory cytokines, such as IL-12 and
IL-6, ensues (5–7). Although full-length BCAP (BCAP-L)FIGURE 2 The competition in the TLR pathway
due to overlapping binding sites. Most of the nega-
tive regulators and the proteins that lead to distinct
parallel paths of TLRs compete with one another
to bind to a common partner. The TIR domain-con-
taining proteins all compete to bind to each other;
IRAK4 and FADD compete to bind to overlapping
interfaces on DD of MyD88; TRAF6 and TRAF3
have shared interfaces on MyD88-DD. Deubiqui-
tinases, such as A20, CYLD, and DUBA removes
Ub chains from TRAF6 and TRAF3. To see this
figure in color, go online.
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ity, truncated BCAP (BCAP-S) that lacks TIR domain is
unable to do so (3,6), suggesting that its TIR domain is
critical for TLR regulation. BCAP recruitment and the
resulting PI3K activation serve as a checkpoint to limit
TLR-induced inflammation (5). BCAP represses MyD88-
dependent NF-kB and MAPK activation and there might
be two different scenarios for this: in the first, BCAP inter-
feres with the TIR domain signalosome (6,31). In the
second, BCAP may allow signalosome formation and func-
tion downstream of MyD88 but still interfere with the
conventional downstream NF-kB pathway; because Akt is
not activated in the absence of MyD88 in macrophages (6)
and MyD88 is vital for the recruitment of PI3K p85 regula-
tory subunit (30).
Our results show that the TIR domain of BCAP can form
potential complexes with all TIR-domain-containing pro-
teins in TLR signaling, including TLR4, Mal, MyD88,
TRAM, and TRIF (Fig. 3). The details of each of the inter-
action architectures are given in Tables 1 and S2. Some of
these interactions interfere with TIR domain signalosomeFIGURE 3 BCAP interactions with all TIR domain-containing proteins in TL
TLR4-Mal interaction, Mal-dimerization, and the entire MyD88-dependent si
with TLR4-TRAM binding therefore these two interactions are mutually exclus
action with Mal hinders its dimerization and the assembly of MyD88-dependen
mation. (e) BCAP-TRAM interaction interferes with TRAM-dimerization and p
blocks TRIF-TRAM interaction due to overlapping binding sites. Red boxes indic
red-labeled regions are the BB-loops of the proteins. In all parts, the left-hand si
right-hand side schematic figure shows the TIR domain signalosome and how the
matics represent the TIR domains: cyan represents TLR, yellow represents Mal, p
and orange represents BCAP. To see this figure in color, go online.formation, supporting the first scenario. For instance, if
BCAP binds to TLR4, it abolishes TLR4-TRAM interaction
due to steric clash of BCAP and TRAM, preventing TRIF-
dependent signal relay (Fig. 3 b). Moreover, if it binds to
Mal, due to overlapping binding sites the Mal-BCAP inter-
action prevents Mal homodimerization, which is vital for
MyD88-dependent signalosome formation (32) (Fig. 3 c).
Similar to MyD88, TRIF can also mediate PI3K acti-
vation (33), but the IL-10 level does not change in the
absence of BCAP (5). BCAP-TRAM interaction abrogates
TRAM homodimerization (Fig. 3 e), which facilitates
TRIF recruitment by serving as a binding platform (34)
and the BCAP-TRIF association disrupts TRAM-TRIF
interaction (Fig. 3 f).
In addition to interfering with the formation of TIR-
domain signalosome, our results indicate that the second
scenario is also plausible. For instance, BCAP-TLR4
enables MyD88-dependent signalosome formation, as it
does not abolish TLR4-dimerization or TLR4-Mal interac-
tion (Fig. 3 a). Moreover, the interaction of BCAP with
MyD88 does not intrude into MyD88-dimerization interfaceR signaling. (a) BCAP interaction with TLR4 allows TLR4 dimerization,
gnalosome formation. (b) BCAP interaction with TLR4 has steric clash
ive: if BCAP binds to TLR4, TRAM cannot bind to TLR4. (c) BCAP inter-
t signalosome. (d) BCAP-MyD88 interaction enables the signalosome for-
revents TRIF-dependent signalosome assembly. (f) BCAP-TRIF interaction
ate the location of clash and therefore those complexes are not possible. The
de figure shows the structure of PPI complexes obtained by PRISM, and the
negative regulators affect the assembly of signalosome. Circles in the sche-
urple represents MyD88, light pink represents TRAM, blue represents TRIF
Biophysical Journal 109(6) 1214–1226
TABLE 1 Details of interactions that are predicted by PRISM
PPI Protein1 Protein2
Template
Interface
Interaction
Energy Reference
BCAP-TLR4 model model 3dahAB 46.7
BCAP-Mal model 4lqdA 3urrAB 57.21 (6)
BCAP-MyD88 model 4eo7A 3f1rAB 39.95 (6,30)
BCAP-TRAM model 2m1wA 3bdvAB 27.05
BCAP-TRIF model 2m1xA 3dhxAB 29.97 (33)
SIGIRR-TLR4 model model 3imoBD 22.7 (7,38–40)
SIGIRR-Mal model 4fz5A 1unhBE 36.06
SIGIRR-MyD88 model 4domA 3f13AB 27.84 (39,40)
SIGIRR-TRAM model 2m1wA 1pzmAB 11.38
SIGIRR-TRIF model 2m1xA 1ntcAB 21.38 (43,44)
ST2L-TLR4 model model 2bq1EF 16.67 (40)
ST2L-Mal model 3ub2A 3urrAB 40.66 (29)
ST2L-MyD88 model 4eo7A 2oh1CD 18.47 (29,39,40)
ST2L-TRAM model 2m1wA 3sf8AB 43.48
ST2L-TRIF model 2m1xA 3grzAB 22.39
TRAF6-p62 2k0bX 3hctA 3jygAB 12.09 (67)
p62-CYLD 1q02A 1whmA 2yvzAB 20.64 (61,63,64)
TRAF6-CYLD 1whlA 3hcuA 2ekyBD 21.28 (62)
TRAF6-A20 3hcsA 3zjgB 1f5qAB 32.08 (56)
A20 dimer 2vfjB 2vfjC 3dkbCF 48.57 (54)
TRAF3-DUBA 3tmp 1fllA 2a6aAB 16.29 (70)
1218 Guven-Maiorov et al.and allow signalosome formation (Fig. 3 d). Therefore, if
BCAP does not disrupt signalosome formation and func-
tions downstream of MyD88, how does it inhibit NF-kB?
Because BCAP is a large protein (811 residues), it was
suggested that it may interfere with the formation of the
myddosome structure, which is composed of death domains
(DDs) of MyD88, IRAK4, and IRAK2/1 (35). Our results
indicate that when MyD88 binds to BCAP through its
TIR domain, it may not be able to oligomerize with other
MyD88 and IRAK molecules through its DD due to steric
clash that BCAP may cause. Assembly into large complexes
and receptor clustering has been shown to activate signaling
cascades even in the absence of essential ligands (36), prob-
ably via allosteric activation.
Structural details of the interactions allow us to charac-
terize the mechanisms of oncogenic mutations. We mapped
the clinically observed cancer mutations onto interfaces
of the PPI architectures that we generated and performed
in silico mutagenesis. There are 12 oncogenic mutations
on BCAP that fall onto the interface residues (Table 2).
Our in silico mutagenesis analysis revealed that seven
of these mutations abolish BCAP interactions with either
one of five TIR domain-containing proteins (TLR4, Mal,
MyD88, TRAM, and TRIF). These mutations are observed
in melanoma, breast, lung, head and neck, colorectal and
stomach cancers. They do not cluster at a specific location
on the BCAP structure; rather they disperse almost
over the entire BCAP structure (Fig. S1). A recent study
showed that disease-causing mutations often change the
number of hydrogen-bonds and salt bridges in comparison
to nondisease-causing counterparts (37). In line with this,
we found that the E50K mutation on BCAP decreasedBiophysical Journal 109(6) 1214–1226the number of intermolecular H-bonds by 1 and salt bridges
by 2 in the BCAP-TLR4 interaction. Moreover, K139fs
frameshift mutation reduced the number of salt bridges
from seven to four in the BCAP-TRAM interaction. These
decreases in intermolecular bonds may also contribute to
loss of the interaction with the mutant BCAP. Additionally,
there is also a nonsense mutation (G9*) on BCAP seen
in stomach cancer (Table S3) that causes the loss of
BCAP and its interactions. Attenuation of the interactions
liberates the conventional TLR downstream pathway that
leads to NF-kB and MAPK activation and proinflamma-
tory cytokine production. Without a checkpoint to restrict
TLR signaling, constitutive production of inflammatory
cytokines leads to chronic inflammation, which promotes
tumorigenesis.SIGIRR
An orphan receptor SIGIRR (also known as TIR8) has a sin-
gle extracellular immunoglobulin domain, a transmembrane
domain, a cytoplasmic TIR domain, and an unusually long
tail (95 residues), which is missing in other TIR domain-
containing receptors (7,38,39). SIGIRR inhibits NF-kB
activation induced by only TIR domain-containing recep-
tors, like TLR and IL-1R1, but not the others such as tumor
necrosis factor receptor that do not possess a TIR domain
(7). Increased production of inflammatory cytokines and
chemokines has been reported in SIGIRR-deficient mice af-
ter IL-1 and LPS administration (28). Mice lacking SIGIRR
have been shown to be more prone to develop intestinal
tumors (39). The mechanism of inhibition of TLRs by
SIGIRR remains unclear (40). Although its extracellular
immunoglobulin and intracellular TIR domains restrain
IL1 signaling by blocking the interaction between IL-1R1
and IL-1RAP, only its TIR domain inhibits TLR signaling
(41). In particular, the BB-loop of its TIR domain appears
important in association with TLRs, because deletion of
the BB-loop abolished the inhibitory role of SIGIRR
(39,42). The BB-loop is conserved among TIR domain-con-
taining proteins (34).
SIGIRR could either interfere with the organization of
TIR domain signalosome (39–41) or block the translocation
of this complex from the receptor (28). It can form hetero-
dimers with TLR4 (40) and decrease the recruitment of
MyD88 and IRAK4 to activated TLR4 (41). We found
that SIGIRR can interact with all TIR domain-containing
proteins in the TLR pathway (Fig. 4). SIGIRR’s BB-loop
is not involved in its interactions with Mal and TRAM,
but close to the interface region in the MyD88, TLR4, and
TRIF interactions. Similar to BCAP, SIGIRR interactions
with Mal, TRAM, and TRIF interfere with Mal-homodime-
rization (Fig. 4 c), TRAM-homodimerization (Fig. 4 e),
and TRIF-TRAM (Fig. 4 f) interactions, respectively;
hence, they prevent the signalosome assembly. In addition
to the MyD88-dependent pathway, SIGIRR also modulates
TABLE 2 Details of clinically observed mutations on negative regulators of TLRs
Cancer Study Mutation
Mutation
Type Protein Interface of PPI Disrupted PPI
Energy
Score
Difference of
Energy Scores
Melanoma (TCGA) G48S missense BCAP BCAP-TLR4 none 40.33 6.37
NCI-60 E50K missense BCAP BCAP-TLR4 BCAP-TLR4 8.9 37.8
Melanoma (Broad) P82L missense BCAP BCAP-TLR4 BCAP-TLR4 7.7 39
Melanoma (Yale) D113H missense BCAP BCAP-TLR4, BCAP-TRAM none 13.0 33.7
16.97 10.08
Breast (TCGA pub) E21K missense BCAP BCAP-Mal, BCAP-TRIF BCAP-TRIF 25.16 32.05
9.26 20.71
Lung squ (TCGA) L27Q missense BCAP BCAP-Mal, BCAP-TRIF BCAP-TRIF 51.4 5.81
1.18 28.79
Uterine (TCGA) V134M missense BCAP BCAP-Mal none 44.24 12.97
Head & neck (Broad) A136D missense BCAP BCAP-Mal BCAP-Mal none none
Melanoma (Broad) L60F missense BCAP BCAP-MyD88 none 41.88 -1.93
Colorectal (Genentech) C66Y missense BCAP BCAP-MyD88 BCAP-MyD88 12.12 52.07
Stomach (TCGA pub) K139fs FS del BCAP BCAP-TRAM BCAP-TRAM 4.87 22.18
Head & neck (TCGA) S39N missense BCAP BCAP-TRIF none 11.92 18.05
pRCC (TCGA) L282M missense SIGIRR SIGIRR-Mal, SIGIRR-TRIF SIGIRR-TRIF 33.01 3.05
9.84 11.54
Cervical (TCGA) S297F missense SIGIRR SIGIRR-Mal none 22.88 11.18
Breast (TCGA) Y377N missense ST2 ST2-TLR4 none 11.99 4.68
Melanoma (TCGA) P384Q missense ST2 ST2-TLR4 ST2-TLR4 5.45 11.22
Melanoma (TCGA) P406L missense ST2 ST2-TLR4 none 12.45 4.22
Melanoma (Yale) E410K missense ST2 ST2-TLR4 none 14.96 1.71
Lung adeno (TCGA pub) L425Q missense ST2 ST2-TLR4 ST2-TLR4 2.06 18.73
Melanoma (TCGA),
Melanoma (Yale)
R439Q missense ST2 ST2-TLR4 none 19.3 -2.63
Stomach (TCGA) E226K missense CYLD CYLD-p62 none 20.38 0.26
Melanoma (TCGA) P229S missense CYLD CYLD-p62 none 18.34 2.3
Head & neck (TCGA) N300S missense CYLD CYLD-p62 none 15.82 4.82
Uterine (TCGA) I303V missense CYLD CYLD-p62 CYLD-p62 none none
Lung adeno (TCGA) A305S missense CYLD CYLD-p62 none 16.7 3.94
ccRCC (TCGA) P130T missense CYLD CYLD-TRAF6 none 10.35 10.93
Uterine (TCGA) L186R missense CYLD CYLD-TRAF6 none 13.92 7.36
Energy score below 10 indicates favorable interaction. If the difference of energy scores between mutant and wild-type is positive, the mutation is then
destabilizing.
Regulation of TLR-Meditated Inflammation 1219the TRIF-dependent pathway, because it also inhibits TLR3
signaling (43,44), which signals only through TRIF, but not
MyD88. The architectures suggest that the mechanism of
this inhibition is by SIGIRR blocking TRAM-homodimeri-
zation (Fig. 4 e), TLR4-TRAM (Fig. 4 b), and TRIF-TRAM
(Fig. 4 f) interactions.
TLR4-SIGIRR (Fig. 4 a) and MyD88-SIGIRR (Fig. 4 d)
architectures are feasible with the MyD88-dependent sig-
nalosome formation. Although it has been proposed to hind-
er MyD88 homodimerization (39,40), which is vital for
myddosome formation (45,46), our model suggests that
it abolishes neither MyD88-dimerization nor signalosome
organization. Therefore, if TLR4 or MyD88 are the proteins
that SIGIRR interact with and they do not interfere with
the signalosome, how does it hinder the transmission of
the signal from TLR4 to NF-kB? The answer could lie
in the inhibition of the translocation of this complex from
the receptor (28). This strategy is also used by other negative
regulators of TLRs, such as IRAK-M, which prevents the
dissociation of the myddosome structure from the receptor
complex (8,47).SIGIRR has only two clinically observed oncogenic mu-
tations in the interface (Table 2). Only one of the mutations
(L282M) falls on the SIGIRR-Mal and SIGIRR-TRIF inter-
faces and it abrogated the SIGIRR-TRIF interaction. It also
has a nonsense mutation (Q111*) and a frameshift mutation
(P2fs) (Table S3) that produce truncated SIGIRR lacking a
TIR domain and abolish its interactions presented here.ST2 (ST2L)
ST2 (IL1RL1) is also an orphan receptor with a cytoplasmic
TIR domain (7). It inhibits NF-kB activation in response
to IL-1R1 and TLR stimulation (29). Overexpression of
ST2 prevents activation by TLR4- but not TLR3-induced
NF-kB (TLR3 uses only a TRIF-dependent downstream
path). In addition, ST2 coimmunoprecipitates with Mal
and MyD88, but not with TRIF (29). This suggests that
ST2 has inhibitory roles only in the MyD88-dependent
pathway of TLRs.
As with other TIR domain-containing regulators, we
obtained possible interaction models of ST2 with allBiophysical Journal 109(6) 1214–1226
FIGURE 4 SIGIRR interactions with all TIR domain-containing proteins in TLR signaling. (a) SIGIRR interaction with TLR4 allows TLR4 dimerization,
TLR4-Mal interaction, Mal-dimerization, and the entire MyD88-dependent signalosome formation. (b) SIGIRR-TLR4 interaction has steric clash with
TLR4-TRAM binding therefore these two interactions are mutually exclusive: if SIGIRR binds to TLR4, TRAM cannot bind to TLR4. (c) SIGIRR inter-
action with Mal hinders its dimerization and the assembly of MyD88-dependent signalosome. (d) SIGIRR-MyD88 interaction enables the signalosome for-
mation. (e) SIGIRR-TRAM interaction interferes with TRAM-dimerization and prevents TRIF-dependent signalosome assembly. (f) SIGIRR-TRIF
interaction blocks TRIF-TRAM interaction due to overlapping binding sites. Red boxes indicate the location of clash. The red-labeled regions are the
BB-loops of the proteins. In all parts, the left-hand side figure shows the structure of PPI complexes obtained by PRISM, and the right-hand side schematic
figure shows the TIR domain signalosome and how the negative regulators affect the assembly of signalosome. Circles in the schematics represent the TIR
domains: cyan represents TLR, yellow represents Mal, purple represents MyD88, light pink represents TRAM, blue represents TRIF and green represents
SIGIRR. To see this figure in color, go online.
1220 Guven-Maiorov et al.TIR domain-containing proteins in TLR signaling (Fig. 5).
Although its interactions with TLR4 (Fig. 5 a), MyD88
(Fig. 5 d), and TRAM (Fig. 5 e) allow homodimerization
of these proteins, its interactions with Mal and TRIF
abolish Mal-homodimerization (Fig. 5 c) and TRAM-
TRIF interaction (Fig. 5 f). Although it may not interact
with TRAM or TRIF under physiological conditions
(another protein may prevent the association or the pro-
teins may not be coexpressed), PRISM still finds these
interactions.
In mice, ST2 loses its inhibitory action in a proline-to-his-
tidine mutation at position 431 of its TIR domain (7,29).
This residue corresponds to P426 in the human homolog.
P426 is found at the BB-loop of ST2, which is estimated
by alignment of the ST2 structure with other TIR domains.
This residue is on the TLR4-ST2 and TRIF-ST2 interfaces
(Fig. 6) and the P426H mutation abolishes TLR4-ST2 inter-
action. In addition to this mutation, there are six oncogenic
mutations on the interfaces of ST2 (Table 2) and two of
them impede the ST2-TLR4 interaction. There are also eight
nonsense and frameshift mutations on ST2 (Table S3), lead-Biophysical Journal 109(6) 1214–1226ing to loss of the TIR domain and all interactions with the
TIR-containing proteins.Ubiquitinases and deubiquitinases as regulators
of TLR signaling
Ubiquitination is a reversible posttranslational modifica-
tion and it is one of the most prevalent in TLR signaling
and NF-kB activation (48), like phosphorylation (49,50).
Different ubiquitination modes may result in opposing out-
comes, like degradation or signaling of TRAF3 (51). Ub
chains serve as an anchor, assisting in the assembly of large
protein complexes. For instance, the K63-linked Ub chain
attached to TRAF6 recruits TAB2/3 and NEMO (IKK-g);
however, these proteins do not associate directly with
TRAF6 itself. Because NF-kB activation depends on ubiqui-
tination, evolution developed Ub-dependent regulation to
abate inflammation (52). Some of the negative modulators
of the TLR pathway are ubiqutinases that add K48-linked
Ub chains to essential orchestrators. TRIAD3A catalyzes
the K48-linked ubiquitination and leads to proteosomal
FIGURE 5 ST2 interactions with all TIR domain-containing proteins in TLR signaling. (a and b) ST2 interaction with TLR4 allows TLR4 dimerization,
Mal-dimerization, and TRAM dimerization and the formation of bothMyD88- and TRIF-dependent signalosomes. (c) ST2-Mal interaction hinders its dimer-
ization and the assembly of Myd88-dependent signalosome. (d) ST2-MyD88 interaction enables the signalosome formation. (e) ST2-TRAM interaction
interferes with TRAM-TRIF. (f) ST2-TRIF interaction blocks TRIF-TRAM interaction due to overlapping binding sites. Red boxes indicate the location
of clash. The red-labeled regions are the BB-loops of the proteins. In all parts, the left-hand side figure shows the structure of PPI complexes obtained
by PRISM, and the right-hand side schematic figure shows the TIR domain signalosome and how the negative regulators affect the assembly of signalosome.
Circles in the schematics represent the TIR domains: cyan represents TLR, yellow represents Mal, purple represents MyD88, light pink represents TRAM,
blue represents TRIF and dark gray represents ST2. To see this figure in color, go online.
Regulation of TLR-Meditated Inflammation 1221degradation of Mal and TRIF (48); and Nrdp1 adds K48-Ub
to MyD88, inhibits the MyD88-dependent TLR pathway
and preferentially enhances TRIF-dependent IFN expression(53). Some others are deubiquitinases (DUBs), such as A20
(also known as TNFAIP3), CYLD (cylindromatosis D),
and DUBA (deubiquitinating enzyme A), which negativelyFIGURE 6 P426 residue of ST2 is at the inter-
face of its interactions with (a) TLR4 and (b)
TRIF. P426H mutation abolishes TLR4-ST2 inter-
action. The red-labeled regions are the BB-loops
of the proteins. To see this figure in color, go on-
line.
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1222 Guven-Maiorov et al.modulate TLR signaling by removing the K63-linked Ub
chains from proteins, such as TRAF6 and TRAF3 (48).
Below we demonstrate that these key DUBs turn off TLR
signaling because they prevent the binding of TRAF6 and
TRAF3 to their partners in addition to removing their Ub
chains.A20
A20 is a pleiotropic Ub editing enzyme: it has an N-termi-
nal ovarian tumor (OTU) domain with DUB activity, and
seven C-terminal zinc finger domains (ZF)—the fourth
(ZF4) with E3 ligase activity (54,55). Although it is a
DUB, it also catalyzes the addition of K48-linked Ub
chains (56,57). It antagonizes TLR- and tumor necrosis
factor receptor-mediated NF-kB activation (57). TRAF6
is a substrate for A20 in the TLR pathway (48). A20 was
also proposed to inhibit the association of TRAF6 (E3)
with Ubc13 (E2) and UbcH5c (E2) (56). A20 forms homo-
dimers through the ZF4 domains and its higher-order olig-
omerization facilitates its deubiquitinase, E3 ligase and
Ub-binding functions (54). The A20 homodimer structures
in the asymmetric unit of two pdb entries (3dkb_CF and
2vfj_BC) were suggested to be biological because mutation
of the interface residues (M15A, R16E, and H351A) sup-
pressed A20-dimerization (54). We obtained similar homo-
dimer with PRISM (Fig. S2 a).
We found interactions between the RING domain of
TRAF6 and the OTU domain of A20 (Fig. 7) and this archi-
tecture also allows A20 homodimerization (Fig. S2 b). A20-
TRAF6 interaction abolishes TRAF6-Ubc13 as proposed
earlier (56,57), because they have overlapping bindingBiophysical Journal 109(6) 1214–1226sites on TRAF6. C103, H256, and T97 residues on A20
were determined to be the catalytic residues (57). The
C103A mutation inhibits A20 catalytic function (C103A
mutant of A20 was unable to deubiquitinate TRAF6) (57)
and TRAF2-Ubc13 interaction (58). However, this residue
is not on the interface of TRAF6-A20 that we obtained.
This result is expected because C103A mutant of A20
was shown to still bind to TRAF6 (59). The reason for the
blockage of TRAF2-Ubc13 interaction may be that the
C103 residue is involved in the interface of TRAF2-A20
complex; alternatively, mutation of this residue disrupts
the stability of A20 and allosterically modifies its interac-
tion sites. In addition to inhibition of E2-E3 interactions,
A20 has also roles in degradation of E2 proteins (e.g.,
Ubc13) by attaching K48-linked Ub chains to E2, thus
affecting E2-dependent E3 function (60). We could not
find clinically observed oncogenic mutations on A20 that
fall onto A20-TRAF6 interface residues or nonsense/frame-
shift mutations that lead to truncated A20 without OTU
domain the TCGA database.CYLD
CYLD is a Ub-specific protease with a tumor suppressive
role. It removes K63-linked Ub chains from TRAF6 (48)
and negatively regulates NF-kB and expression of proin-
flammatory cytokines (61,62). To date, its NF-kB inhibition
mechanism has been unclear. CYLD interacts with TRAF6
(62), but it was also suggested to require some bridging
adaptor proteins, like p62 (also known as sequestosome1)
to interact with its substrates because its activity is reduced
in the absence of p62 (61,63,64).FIGURE 7 A20 interaction with TRAF6. (a)
OTU domain of A20 interacts with RING domain
of TRAF6. (b) Ubc13 and A20 have almost
completely overlapping interfaces on TRAF6 and
hence their interactions with TRAF6 are mutually
exclusive. Red square indicates the location of
clash. TRAF6-Ubc13 interaction is obtained from
crystal structure (3hcu_AB). (c) TRAF6-dimer
through its RING domain and its interactions
with A20 and Ubc13. To see this figure in color,
go online.
Regulation of TLR-Meditated Inflammation 1223We found TRAF6 interactions with CYLD either via
direct binding or via p62 (Fig. 8, a and b). CYLD has
three CAP-Gly (cytoskeleton-associated protein-glycine
conserved) domains with similar global folds. The third
is suggested to interact with TRAF2 (65,66). As to direct
interaction, we found that the first CAP-Gly domain of
CYLD binds to the RING domain of TRAF6. However,
in the p62 adaptor case, the second CAP-Gly domain of
CYLD interacts with p62, which interacts with TRAF6.
Residues 225–255 of p62 were already identified as an
interface that binds to TRAF6 (67) and this is in agree-
ment with our TRAF6-p62 complex architecture. Both
the direct and indirect (through p62) associations steri-
cally hinder the TRAF6-Ubc13 interaction (Fig. 8, c
and d). If p62-CYLD or CYLD-itself binds this interface
on TRAF6, Ubc13 cannot approach that site and TRAF6
is nonfunctional.
Why does TLR negative regulation have redundant
players with the same function and the same substrate
(TRAF6 with K63-Ub chain), such as A20 and CYLD?
The timing of their action may address this question:
CYLD is constitutively expressed, but A20 is not (61).
Alternatively, they may act in distinct cell types, or subcel-
lular locations (68). They may also cooperate to remove the
Ub chains from TRAF6.
Seven missense mutations on CYLD correspond to the
interface residues, but only one of them causes the loss of
its interactions (p62-CYLD) according to our results (Ta-
ble 2). Additionally, there are also six nonsense or frameshift
mutations that lead to truncated protein without CAP-Gly or
DUB domains (Table S3). Because these mutations cause
loss of the domains that are required for CYLD-TRAF6 or
CYLD-p62 interactions, the truncated CYLD can no longerassociate with these proteins and deubiquitinate TRAF6.
Nonsense and frameshiftmutations predominantly constitute
the mutations of CYLD in tumors (59,69).DUBA (OTUD5)
Similar to A20, DUBA (also known as OTUD5) is also an
OTU domain family member cysteine protease. It sup-
presses IFN-I production in response to TLR activation by
removing K63-Ub chains from TRAF3 and preventing
recruitment of TBK1 and other downstream proteins, which
are necessary for NF-kB and IRF activation (48,51,70).
Interaction of endogenous TRAF3 and DUBA takes place
upon TLR3 stimulation (70). The D221, C224, and H334
are the catalytic residues of DUBA and C224S mutation
on DUBA compromised its function (deubiquitinating
TRAF3) (70). There is less Ub alteration in TRAF3 lacking
a RING domain (70), indicating that the RING domain
of TRAF3 is probably the interaction region. However, we
could not find interaction between the RING domain of
TRAF3 and catalytic OTU domain of DUBA. Instead, we
found interaction with concave site on TRAF-C region
of TRAF3 (Fig. 9). This concave region is where TRAF3
interacts with CD40 (1fll.pdb) (71), BAFFR (2gkw.pdb)
(72), LMP1 (1zms.pdb) (73), Cardif (4ghu.pdb) (74), and
also MyD88 (10). If DUBA also binds to TRAF-C region
in addition to the RING domain of TRAF3, it attenuates
TLR-induced IRF activation not only through its catalytic
(DUB) function, but also through interfering with the
TRAF3 interactions with other signaling proteins. There
are no clinically observed oncogenic mutations on
DUBA that fall onto DUBA-TRAF3 interface residues or
nonsense/frameshift mutations.FIGURE 8 Architectures of direct and indirect
interactions of TRAF6 with CYLD. (a) Indirect as-
sociation of TRAF6 with CYLD through p62
bridging adaptor. (b) Direct interaction of TRAF6
with CYLD. (c) In the p62 case, both p62 and
CYLD has steric clashes with Ubc13. (d) In the
direct binding, CYLD has steric clash with
Ubc13. Red squares indicate the location of clash.
TRAF6-Ubc13 interaction is obtained from crystal
structure (3hcu_AB). To see this figure in color, go
online.
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FIGURE 9 The architecture of the interaction
between the OTU domain of DUBA and TRAF-C
domain of TRAF3. To see this figure in color, go
online.
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The TLR pathway activates different parallel downstream
paths. The conventional downstream path of TLRs is
the MyD88-dependent path, which involves TRAF6 and
IRAKs to activate NF-kB and MAPK and to produce proin-
flammatory cytokines. There are also TRIF-dependent,
TRAF3-dependent, Fas associated death-domain protein
(FADD)-dependent, and BCAP-dependent paths, which
lead to production of IFNs apoptosis, or activation of the
PI3K pathway, respectively. Our recent study (10) suggests
that almost all parallel pathways of TLRs compete with each
other and thus restrict the activation of one another due to
overlapping binding sites on a common binding partner
(Fig. 2). These parallel paths only switch the function: while
negatively regulating one path, they positively regulate
others. The negative regulators covered in this study, except
BCAP, cease TLR signaling. Network flow algorithms
might be helpful to understand the interplay between paral-
lel paths in TLR pathway (75).CONCLUSIONS
The TLR pathway resembles a double-edged sword: On the
one hand, it is vital for triggering proper host immune
response against pathogens and its malfunction makes
individuals more susceptible to infections. On the other,
its overactivation results in excess inflammation, which is
detrimental to the host. The cell has evolved several mech-
anisms to strike a balance between activation and inhibition
of TLR signaling at almost each step of the pathway.
Although several negative regulators have been identified,
their inhibition mechanisms remain elusive. Here, we pro-
vide the structural basis for the regulation of TLR signaling.
Overall, we observed that negative regulators tend to inter-
fere with the assembly of key signaling complexes, such as
TIR-domain signalosome, compete with proteins to bind to
their partners, and modify ubiquitination states and target
them for proteosomal degradation. Similarly, parallel down-
stream paths compete with each other and restrain their acti-
vation. Several oncogenic mutations on negative modulatorsBiophysical Journal 109(6) 1214–1226tend to disrupt their interactions with the key players in
TLR pathway, liberating the conventional downstream
path and constitutive activation of NF-kB. Better under-
standing of negative regulation of TLR signaling holds
promise for novel treatment strategies for autoimmune dis-
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